|
|
|
|
Gene discovery may help doctors tailor bowl cancer treatment
A new genetic study has taken scientists a step closer to an era of personalised cancer treatment.British experts identified faults in DNA that can help doctors tailor therapies for thousands of patients with bowel cancer.The research is the latest to flag...
|
|
|
Bowel cancer treatment breakthrough
A new genetic study has taken scientists a step closer to an era of personalised cancer treatment.British experts identified faults in DNA that can help doctors tailor therapies for thousands of patients with bowel cancer. The research is the latest to...
|
|
|
Bowel cancer 'hotspots' are found
Bowel cancer is the third most common cancer in the UK Scientists have found genetic hotspots for bowel cancer they say will help doctors better treat the disease.They say a third of the 37,500 people diagnosed with the cancer in the UK each year harbours...
|
|
|
DxS Negotiates PI3K License from JHU to Develop Companion Diagnostics
Cancer GEN News Highlights GEN News Highlights QiagensDxS subsidiary negotiated an exclusive global license to the Johns Hopkins University PI3K biomarker patent for use in the development of PCR-based companion diagnostics for cancer therapies.This license...
|
|
|
QIAGEN Acquires Exclusive Licence for Key PI3K gene - Patent licensed from Johns Hopkins University for PCR-ba
--- QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that its wholly owned subsidiary DxS has acquired the global and exclusive licence for biomarker PI3K from Johns Hopkins University to develop real-time-PCR and endpoint PCR assays.
|
|
|
QIAGEN Acquires Exclusive Licence for Key PI3K gene
QIAGEN ( NASDAQ:QGEN; Frankfurt Prime Standard: QIA) today announced that its wholly owned subsidiary DxS has acquired the global and exclusive licence for biomarker PI3K from Johns Hopkins University to develop real-time-PCR and endpoint PCR assays.Research...
|
|
|
QIAGEN acquires global licence for PI3K gene to develop real-time-PCR and endpoint PCR assays
QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that its wholly owned subsidiary DxS has acquired the global and exclusive licence for biomarker PI3K from Johns Hopkins University to develop real-time-PCR and endpoint PCR assays.Research...
|
|
|
QIAGEN Acquires Exclusive Licence for Key PI3K gene
VENLO, The Netherlands, February 8 /PRNewswire-FirstCall/ -- QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that its wholly owned subsidiary DxS has acquired the global and exclusive licence for biomarker PI3K from Johns Hopkins University...
|
|
|
QIAGEN Acquires Exclusive Licence for Key PI3K gene
VENLO, The Netherlands, February 8 /PRNewswire-FirstCall/ -- QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that its wholly owned subsidiary DxS has acquired the global and exclusive licence for biomarker PI3K from Johns Hopkins University...
|
|
|
QIAGEN Acquires Exclusive Licence for Key PI3K gene
VENLO, The Netherlands, February 8 /PRNewswire-FirstCall/ -- QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that its wholly owned subsidiary DxS has acquired the global and exclusive licence for biomarker PI3K from Johns Hopkins University...
|
|
|
QIAGEN Acquires Exclusive Licence for Key PI3K gene
Patent Licensed From Johns Hopkins University for PCR-based Companion Diagnostics for Cancer Treatments VENLO, The Netherlands, February 8/PRNewswire-FirstCall/ -- QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that its wholly owned...
|
|
|
Pfizer Q4 2009 Earnings Call Transcript
Pfizer Inc.(PFE) Q4 2009 Earnings Call Transcript Executives Charles E. Triano Senior Vice President of IR Jeffrey B. Kindler Chairman and Chief Executive Officer Frank A. D''Amelio Senior Vice President and Chief Financial Officer Ian C. Read -...
|
|
|
Pfizer Q4 2009 Earnings Call Transcript
Pfizer Inc.(PFE) Q4 2009 Earnings Call Transcript Executives Charles E. Triano Senior Vice President of IR Jeffrey B. Kindler Chairman and Chief Executive Officer Frank A. D''Amelio Senior Vice President and Chief Financial Officer Ian C. Read -...
|
|
|
QIAGEN Acquires Exclusive Licence for Key PI3K gene
Patent Licensed From Johns Hopkins University for PCR-based Companion Diagnostics for Cancer Treatments PR Newswire VENLO, The Netherlands, February 8 /PRNewswire-FirstCall/ -- QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that its wholly...
|
|
|
QIAGEN Acquires Exclusive Licence for Key PI3K gene
Patent Licensed From Johns Hopkins University for PCR-based Companion Diagnostics for Cancer Treatments PR Newswire VENLO, The Netherlands, February 8 /PRNewswire-FirstCall/ -- QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that its wholly...
|
|
|
QIAGEN Acquires Exclusive Licence for Key PI3K gene
Patent Licensed From Johns Hopkins University for PCR-based Companion Diagnostics for Cancer Treatments PR Newswire VENLO, The Netherlands, February 8 /PRNewswire-FirstCall/ -- QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that its wholly...
|
|
|
QIAGEN Acquires Exclusive Licence for Key PI3K gene
Patent Licensed From Johns Hopkins University for PCR-based Companion Diagnostics for Cancer Treatments PR Newswire VENLO, The Netherlands, February 8 /PRNewswire-FirstCall/ -- QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that its wholly...
|
|
|
QIAGEN Acquires Exclusive Licence for Key PI3K gene
Patent Licensed From Johns Hopkins University for PCR-based Companion Diagnostics for Cancer Treatments PR Newswire VENLO, The Netherlands, February 8 /PRNewswire-FirstCall/ -- QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that its wholly...
|
|
|
QIAGEN Acquires Exclusive Licence for Key PI3K gene
Patent Licensed From Johns Hopkins University for PCR-based Companion Diagnostics for Cancer Treatments PR Newswire VENLO, The Netherlands, February 8 /PRNewswire-FirstCall/ -- QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that its wholly...
|
|
|
QIAGEN Acquires Exclusive Licence for Key PI3K gene
Patent Licensed From Johns Hopkins University for PCR-based Companion Diagnostics for Cancer Treatments PR Newswire VENLO, The Netherlands, February 8 /PRNewswire-FirstCall/ -- QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that its wholly...
|
|
|
QIAGEN Acquires Exclusive Licence for Key PI3K gene
(PR Newswire Europe via COMTEX) ----Patent Licensed From Johns Hopkins University for PCR-based Companion Diagnostics for Cancer Treatments QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that its wholly owned subsidiary DxS has acquired...
|
|
|
QIAGEN Acquires Exclusive Licence for Key PI3K gene - Zibb.com
Company: Qiagen N.V.(QGEN) Patent Licensed From Johns Hopkins University for PCR-based Companion Diagnostics for Cancer Treatments QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that its wholly owned subsidiary DxS has acquired the...
|
|
|
QIAGEN Acquires Exclusive Licence for Key PI3K gene
Patent Licensed From Johns Hopkins University for PCR-based Companion Diagnostics for Cancer Treatments PR Newswire VENLO, The Netherlands, February 8 /PRNewswire-FirstCall/ -- QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that its wholly...
|
|
|
QIAGEN Acquires Exclusive Licence for Key PI3K gene
Patent Licensed From Johns Hopkins University for PCR-based Companion Diagnostics for Cancer Treatments PR Newswire VENLO, The Netherlands, February 8 /PRNewswire-FirstCall/ -- QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that its wholly...
|
|
|
QIAGEN Acquires Exclusive Licence for Key PI3K gene
Patent Licensed From Johns Hopkins University for PCR-based Companion Diagnostics for Cancer Treatments PR Newswire VENLO, The Netherlands, February 8 /PRNewswire-FirstCall/ -- QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that its wholly...
|
